Edition:
United Kingdom

WAVE Life Sciences Ltd (WVE.OQ)

WVE.OQ on NASDAQ Stock Exchange Global Market

38.00USD
13 Dec 2017
Change (% chg)

$0.40 (+1.06%)
Prev Close
$37.60
Open
$37.65
Day's High
$38.30
Day's Low
$37.50
Volume
36,070
Avg. Vol
40,267
52-wk High
$39.70
52-wk Low
$15.15

Select another date:

Mon, Dec 11 2017

BRIEF-Wave Life Sciences Reports Data From Preclinical Studies Testing WVE-3972-01

* WAVE LIFE SCIENCES - ANNOUNCED DATA FROM PRECLINICAL STUDIES OF WVE-3972-01 FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA

BRIEF-Wave Life Sciences Q3 net loss of $26.1 million

* Wave Life Sciences reports third quarter 2017 financial results and provides business update

BRIEF-Wave Life Sciences opens new 90,000 square foot manufacturing facility

* Wave Life Sciences Ltd - ‍public opening of its new 90,000 square foot manufacturing facility and office space in Lexington, Massachusetts​ Source text for Eikon: Further company coverage:

BRIEF-Teva pharmaceutical reports 5 pct stake in Wave Life Sciences as of Aug 30, 2017 versus 9 percent stake as of Nov 16, 2015

* Teva Pharmaceutical Industries Limited reports 5 percent stake in Wave Life Sciences Ltd as of Aug 30, 2017 versus 9 percent stake as of Nov 16, 2015 - SEC filing‍​ Source text: (http://bit.ly/2w4qQej) Further company coverage:

BRIEF-Wave Life Sciences qtrly loss per share $0.92‍​

* Wave life sciences reports second quarter 2017 financial results and provides business update

BRIEF-Wave Life Sciences initiates two Phase 1b/2a clinical trials PRECISION-HD1 and PRECISION-HD2 in patients with Huntington’S Disease

* Wave Life Sciences Ltd - ‍trials evaluate first allele-specific investigational drugs for Huntington's Disease, WVE-120101 and WVE-120102​ Source text for Eikon: Further company coverage:

Select another date: